IP Library Granted Patent US 11,090,338
Granted Patent B2
US 11,090,338 · App. 13/929,252 · Granted Aug 17, 2021

Methods for improved treatment of adipose tissue

Inventors: Aaron Barere (Hoboken, NJ); Jerome Connor (Doylestown, PA)
Assignee: LifeCell Corporation
A61K35/35A61L27/3604A61L27/3687A61L2430/34A61L2430/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,090,338
App. No.
13/929,252
Granted
Aug 17, 2021
Kind
B2
Abstract

The present disclosure relates generally to methods of treatment of tissue prior to implantation. In one aspect, the methods of treatment include washing adipose tissue with detergents to improve the viability of adipose cells for implantation and/or to increase the amount of viable adipose cells per volume of tissue for implantation.

Claims (18)

1. A method for treating tissue comprising:

selecting a tissue comprising adipocytes for implantation;

contacting the tissue with a detergent at a concentration and time sufficient to remove non-viable materials comprising blood, water, and particulate tissue matrix from the tissue to produce an adipose tissue comprising adipocytes and adipose extracellular tissue matrix, wherein a poloxamer is not used in the contacting step; and

rinsing the tissue to remove the detergent, such that the contacting and rinsing increase the concentration of viable adipocytes in the tissue as compared to the tissue prior to treatment.

2. The method according to claim 1 , wherein the method is performed prior to implantation of the tissue during autologous fat transfer.

3. The method according to claim 1 , wherein the detergent is a nonionic detergent.

4. The method according to claim 1 , wherein the detergent is a biocompatible detergent.

5. The method according claim 1 , wherein the detergent comprises a polysorbate.

6. The method according to claim 1 , wherein the detergent comprises a polyethylene glycol.

7. The method according to claim 1 , wherein the non-viable materials further comprise pharmaceutical agents and epinephrine.

8. The method according to claim 1 , wherein the tissue is contacted with the detergent and rinsed under conditions selected to reduce the water content of the tissue.

9. The method according to claim 1 , further comprising agitating the tissue while the tissue is in contact with the detergent.

10. The method of claim 9 , wherein agitating the tissue comprises at least one of stirring, shaking, and causing the detergent to flow in contact with the tissue.

11. The method according to claim 1 , further comprising repeating the steps of contacting the tissue with the detergent and rinsing the tissue.

12. The method according to claim 1 , wherein the tissue is rinsed with a rinsing fluid comprising a saline solution.

13. The method according to claim 1 , further comprising implanting the tissue in a patient.

14. The method according to claim 1 , further comprising removing water from the tissue.

15. The method according to claim 1 , wherein the contacting and rinsing at least doubles the concentration of viable adipocytes in the tissue as compared to the tissue prior to treatment.

Assignments (7)
RELEASE OF SECURITY INTEREST 037845/0497 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0603 →
RELEASE OF SECURITY INTEREST 040098/0268 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0554 →
RELEASE OF SECURITY INTEREST 040291/0237 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0702 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
SECURITY INTEREST Recorded Feb 17, 2016
From: KINETIC CONCEPTS, INC.; KCI USA, INC.; ACELITY L.P. INC.; CHIRON HOLDINGS, INC.; CHIRON TOPCO, INC.; KCI ANIMAL HEALTH, LLC; KCI HOLDING COMPANY, INC.; KCI HOMECARE, INC.; KCI IMPORTS, INC.; KCI INTERNATIONAL, INC.; KCI LICENSING, INC.; KCI PROPERTIES LIMITED; KCI REAL HOLDINGS, L.L.C.; KCI REAL PROPERTY LIMITED; KCI USA REAL HOLDINGS, L.L.C.; LIFECELL CORPORATION; TECHNIMOTION, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 037845/0497 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2013
From: BARERE, AARON M.; CONNOR, JEROME
To: LIFECELL CORPORATION
Reel/Frame 031555/0048 →
Continuity (2)
Provisional Application 61671443 · Jul 13, 2012
Related Publication 20140017206A1 · Jan 16, 2014
Cited By (1)
US 12,551,509